Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
China · Delayed Price · Currency is CNY 31.11
-0.15 (-0.48%)
At close: Feb 13, 2026
SHA:688217 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 184.42 | 234.95 | 246.05 | 416.06 | 270.59 | 265.07 |
Other Revenue | 7.36 | 7.36 | 12.16 | 8.24 | 20.36 | 19.85 |
| 191.78 | 242.31 | 258.21 | 424.3 | 290.95 | 284.93 | |
Revenue Growth (YoY) | -22.99% | -6.16% | -39.14% | 45.83% | 2.11% | 11.53% |
Cost of Revenue | 54.41 | 62.84 | 70.56 | 166.6 | 78.83 | 81.06 |
Gross Profit | 137.37 | 179.47 | 187.65 | 257.7 | 212.12 | 203.87 |
Selling, General & Admin | 100.26 | 127.32 | 120.9 | 109.76 | 115.31 | 89.75 |
Research & Development | 58.07 | 62.47 | 69.8 | 64.43 | 68.64 | 74.36 |
Other Operating Expenses | 2.55 | 2.18 | 2 | 1.14 | 0.78 | 0.7 |
Operating Expenses | 169.23 | 198.62 | 197.73 | 184.88 | 185.09 | 165.76 |
Operating Income | -31.86 | -19.15 | -10.08 | 72.81 | 27.04 | 38.11 |
Interest Expense | -0.88 | -0.88 | -0.83 | -0.55 | -0.49 | -0.06 |
Interest & Investment Income | 4.83 | 4.79 | 6.49 | 4.74 | 4.08 | 1.61 |
Currency Exchange Gain (Loss) | 0.66 | 0.66 | 0.84 | 4.69 | -1.54 | -4.67 |
Other Non Operating Income (Expenses) | -0.47 | -0.26 | -0.58 | -0.35 | -0.75 | -0.15 |
EBT Excluding Unusual Items | -27.73 | -14.85 | -4.15 | 81.34 | 28.34 | 34.83 |
Impairment of Goodwill | -14.31 | -14.31 | -7.5 | -13.39 | - | - |
Gain (Loss) on Sale of Investments | 1.06 | 0.87 | 0.33 | 0.61 | 2.09 | - |
Gain (Loss) on Sale of Assets | -0.15 | 0.12 | 0.84 | -0.01 | -0.1 | 0.08 |
Asset Writedown | -2.07 | -2.37 | -0.14 | -0.77 | - | -0.12 |
Other Unusual Items | 1.57 | 2.05 | 1.22 | 3.7 | 12.12 | 5.29 |
Pretax Income | -41.62 | -28.47 | -9.4 | 71.48 | 42.45 | 40.09 |
Income Tax Expense | -1.86 | -2.57 | -4.6 | 5.56 | 2.37 | 1.27 |
Earnings From Continuing Operations | -39.76 | -25.91 | -4.8 | 65.92 | 40.08 | 38.82 |
Minority Interest in Earnings | 12.65 | 10.14 | 12.74 | -25.45 | 7.25 | -0.1 |
Net Income | -27.11 | -15.76 | 7.93 | 40.47 | 47.33 | 38.71 |
Net Income to Common | -27.11 | -15.76 | 7.93 | 40.47 | 47.33 | 38.71 |
Net Income Growth | - | - | -80.41% | -14.49% | 22.26% | 7.69% |
Shares Outstanding (Basic) | 56 | 56 | 57 | 55 | 50 | 42 |
Shares Outstanding (Diluted) | 56 | 56 | 57 | 55 | 50 | 42 |
Shares Change (YoY) | -4.42% | -0.61% | 2.17% | 11.28% | 19.69% | -0.12% |
EPS (Basic) | -0.49 | -0.28 | 0.14 | 0.73 | 0.95 | 0.93 |
EPS (Diluted) | -0.49 | -0.28 | 0.14 | 0.73 | 0.95 | 0.93 |
EPS Growth | - | - | -80.82% | -23.16% | 2.15% | 8.14% |
Free Cash Flow | 3.97 | 20.57 | -64 | -33.5 | -17.63 | 17.97 |
Free Cash Flow Per Share | 0.07 | 0.36 | -1.13 | -0.60 | -0.35 | 0.43 |
Dividend Per Share | 0.170 | - | 0.180 | - | - | - |
Gross Margin | 71.63% | 74.07% | 72.67% | 60.73% | 72.91% | 71.55% |
Operating Margin | -16.61% | -7.90% | -3.91% | 17.16% | 9.29% | 13.37% |
Profit Margin | -14.14% | -6.51% | 3.07% | 9.54% | 16.27% | 13.59% |
Free Cash Flow Margin | 2.07% | 8.49% | -24.79% | -7.90% | -6.06% | 6.31% |
EBITDA | 8.56 | 20.76 | 29.15 | 103.68 | 60.04 | 66.5 |
EBITDA Margin | 4.46% | 8.57% | 11.29% | 24.44% | 20.64% | 23.34% |
D&A For EBITDA | 40.42 | 39.91 | 39.23 | 30.86 | 33 | 28.39 |
EBIT | -31.86 | -19.15 | -10.08 | 72.81 | 27.04 | 38.11 |
EBIT Margin | -16.61% | -7.90% | -3.91% | 17.16% | 9.29% | 13.37% |
Effective Tax Rate | - | - | - | 7.78% | 5.58% | 3.17% |
Revenue as Reported | 191.78 | 242.31 | 258.21 | 424.3 | 290.95 | 284.93 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.